MEMORANDUM OPINION
ANDREWS, District Judge.
Plaintiffs, Pfizer Inc., Wyeth LLC, and Wyeth Pharmaceuticals Inc. (collectively, "Pfizer"), market an anti-transplant rejection medication based on rapamycin, also known as sirolimus, under the trade name Rapamune®. The Food and Drug Administration ("FDA") Orange Book lists U.S. Patent No. 5,100,899 (filed June 6, 1989) in connection with Pfizer's Rapamune® product.
Welcome to the leading source of independent legal reporting
Let's get started
Sign on now to see your case.
Or view more than 10 million decisions and orders.